Welcome to our dedicated page for Omeros SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digesting 200+ pages of Omeros trial data, cash-runway tables, and scientific jargon can stall even seasoned analysts. From tracking complement-pathway breakthroughs to spotting dilution risks, Omeros SEC documents are both pivotal and complex. That鈥檚 why investors searching for 鈥淥meros SEC filings explained simply鈥� or 鈥渉ow to read an Omeros annual report 10-K simplified鈥� land here first.
Stock Titan鈥檚 AI instantly translates every 10-K, 10-Q, 8-K, and Form 4 into clear takeaways. Wondering about 鈥淥meros quarterly earnings report 10-Q filing鈥� or need 鈥淥meros earnings report filing analysis鈥�? Our platform highlights trial milestone updates, R&D spend, and going-concern language in seconds. AG真人官方-time alerts flag 鈥淥meros Form 4 insider transactions real-time鈥� so you never miss executive stock moves, while our side-by-side comparisons reveal trends across periods.
Every filing type is covered and contextually linked to Omeros鈥� business:
- 10-K & 10-Q: Follow liquidity projections, pipeline costs, and safety data鈥攑erfect for 鈥渦nderstanding Omeros SEC documents with AI鈥�.
- 8-K: Immediate insight into clinical readouts and FDA feedback鈥攕earch for 鈥淥meros 8-K material events explained鈥�.
- Form 4: Monitor 鈥淥meros insider trading Form 4 transactions鈥� and 鈥淥meros executive stock transactions Form 4鈥� the moment they post.
- DEF 14A: Explore 鈥淥meros proxy statement executive compensation鈥� without paging through dense tables.
Skip the manual hunt for disclosures. Our AI-powered summaries, expert commentary, and real-time feeds transform Omeros filings into actionable knowledge, letting you focus on valuation, not pagination.
Omeros (OMER) has entered into a registered direct offering of 5,365,853 common shares at $4.10, a 14% premium to the 24-Jul-25 close ($3.59). Gross proceeds total $22.0 million; after the 6% placement fee to D. Boral Capital ($1.32 million) and other expenses, net cash is expected at roughly $20.3 million.
The raise increases shares outstanding from 61.8 million to 67.1 million (鈮�8.7% dilution) and lifts available cash from 鈮�$26 million (18-Jul-25) to >$45 million, funding general corporate uses, clinical and pre-clinical pipeline work and working capital. Management retains broad spending discretion.
Key pipeline points: FDA鈥檚 BLA for lead MASP-2 antibody narsoplimab in TA-TMA now carries a 26-Dec-25 PDUFA date; EMA review is ongoing with an opinion expected mid-2026. The company is also advancing MASP-3 inhibitor zaltenibart (PNH, C3G) and PDE7 program OMS527 (cocaine use disorder). Omeros is negotiating a potential multi-billion-dollar asset deal that could retire its $67.1 million term loan and part of its 2026 notes.
Despite the premium pricing, the offer adds to a $(193 million) adjusted tangible book deficit and follows an auditor going-concern warning. Investors face immediate dilution of $7.15 per share (net tangible book value basis) and future overhang from 19.6 million outstanding options and convertible notes.
FAQ
What is the current stock price of Omeros (OMER)?
What is the market cap of Omeros (OMER)?
